蛋白尿：ONTARGET研究的肾脏亚组研究是否真的偏离了目标？ - Suppr

Suppr

超能文献

Proteinuria: Is the ONTARGET renal substudy actually off target?

作者信息

Ruggenenti Piero, Remuzzi Giuseppe

出版信息

Nat Rev Nephrol. 2009 Aug;5(8):436-7. doi: 10.1038/nrneph.2009.109.

DOI:10.1038/nrneph.2009.109

PMID:19639016

Abstract

摘要

相似文献

Proteinuria: Is the ONTARGET renal substudy actually off target?蛋白尿：ONTARGET研究的肾脏亚组研究是否真的偏离了目标？

Nat Rev Nephrol. 2009 Aug;5(8):436-7. doi: 10.1038/nrneph.2009.109.

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.替米沙坦、雷米普利或二者联用对高血管风险人群的肾脏结局影响（ONTARGET研究）：一项多中心、随机、双盲、对照试验

Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2.

Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.肾素-血管紧张素系统抑制导致肾小球滤过率的急性变化并不能预测随后的肾脏和心血管结局。

Kidney Int. 2017 Mar;91(3):683-690. doi: 10.1016/j.kint.2016.09.038. Epub 2016 Dec 4.

[ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].[ 血管事件高危患者的治疗：替米沙坦、雷米普利还是联合用药？ ]

Internist (Berl). 2008 Sep;49(9):1137-40. doi: 10.1007/s00108-008-2199-4.

[Critically appraised article].[严格评价的文章]

Rev Med Chil. 2012 Jan;140(1):117-20. Epub 2012 Apr 12.

Telmisartan, ramipril, or both in patients at high risk for vascular events.替米沙坦、雷米普利或两者联合用于血管事件高危患者。

N Engl J Med. 2008 Apr 10;358(15):1547-59. doi: 10.1056/NEJMoa0801317. Epub 2008 Mar 31.

ONTARGET should not be over interpreted.ONTARGET研究结果不应被过度解读。

Nephrol Dial Transplant. 2010 Jan;25(1):44-7. doi: 10.1093/ndt/gfp633. Epub 2009 Nov 23.

Is therapy of people with chronic kidney disease ONTARGET?慢性肾病患者的治疗是否达到了目标？

Nephrol Dial Transplant. 2010 Jan;25(1):42-4. doi: 10.1093/ndt/gfp568. Epub 2009 Oct 23.

Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.替米沙坦、雷米普利或两者联合用于高危肾脏人群的心血管和肾脏结局：ONTARGET 和 TRANSCEND 研究结果。

Circulation. 2011 Mar 15;123(10):1098-107. doi: 10.1161/CIRCULATIONAHA.110.964171. Epub 2011 Feb 28.

ONTARGET: questions asked, questions answered.目标试验（ONTARGET）：问题提出，问题解答。

J Clin Hypertens (Greenwich). 2008 Jun;10(6):427-30. doi: 10.1111/j.1751-7176.2008.08509.x.

引用本文的文献

Renin-angiotensin system inhibitors in hypertensive adults with non-diabetic CKD with or without proteinuria: a systematic review and meta-analysis of randomized trials.肾素-血管紧张素系统抑制剂在伴有或不伴有蛋白尿的非糖尿病慢性肾脏病的高血压成人中的应用：一项随机试验的系统评价和荟萃分析。

Hypertens Res. 2019 Apr;42(4):469-482. doi: 10.1038/s41440-018-0116-3. Epub 2019 Apr 5.

Achieving remission of proteinuria in childhood CKD.实现儿童慢性肾脏病蛋白尿的缓解。

Pediatr Nephrol. 2017 Feb;32(2):321-330. doi: 10.1007/s00467-016-3495-1. Epub 2016 Oct 4.

Recent advances in managing and understanding diabetic nephropathy.糖尿病肾病管理与认识的最新进展

F1000Res. 2016 May 31;5. doi: 10.12688/f1000research.7693.1. eCollection 2016.

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis.评估终末期肾病替代结局的有效性：一项荟萃分析。

J Am Soc Nephrol. 2015 Sep;26(9):2289-302. doi: 10.1681/ASN.2014040396. Epub 2015 Jan 2.

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis.药物诱导的蛋白尿减少与后续肾脏保护相关：一项荟萃分析。

J Am Soc Nephrol. 2015 Aug;26(8):2055-64. doi: 10.1681/ASN.2014070688. Epub 2014 Nov 24.

The effect of RAAS blockade on the progression of diabetic nephropathy.RAAS 阻断对糖尿病肾病进展的影响。

Nat Rev Nephrol. 2014 Feb;10(2):77-87. doi: 10.1038/nrneph.2013.251. Epub 2013 Dec 3.

Addition of aliskiren to Angiotensin receptor blocker improves ambulatory blood pressure profile and cardiorenal function better than addition of benazepril in chronic kidney disease.在慢性肾脏病中，与加用贝那普利相比，阿利吉仑联合血管紧张素受体阻滞剂可更好地改善动态血压谱和心肾功能。

Int J Mol Sci. 2013 Jul 24;14(8):15361-75. doi: 10.3390/ijms140815361.

Improving the efficacy of RAAS blockade in patients with chronic kidney disease.提高慢性肾脏病患者 RAAS 阻断的疗效。

Nat Rev Nephrol. 2013 Feb;9(2):112-21. doi: 10.1038/nrneph.2012.281. Epub 2012 Dec 18.

The angiotensin II type 1 receptor blocker olmesartan preferentially improves nocturnal hypertension and proteinuria in chronic kidney disease.血管紧张素 II 型 1 型受体阻滞剂奥美沙坦可优先改善慢性肾脏病患者的夜间高血压和蛋白尿。

Hypertens Res. 2013 Mar;36(3):262-9. doi: 10.1038/hr.2012.184. Epub 2012 Nov 15.

Renovascular and renoprotective properties of telmisartan: clinical utility.替米沙坦的肾血管及肾保护特性：临床应用

Int J Nephrol Renovasc Dis. 2010;3:33-8. doi: 10.2147/ijnrd.s7033. Epub 2010 Mar 16.

本文引用的文献

Re-examining RAS-blocking treatment regimens for abrogating progression of chronic kidney disease.

Nat Clin Pract Nephrol. 2009 Jan;5(1):12-3. doi: 10.1038/ncpneph0980. Epub 2008 Nov 4.

Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection.慢性肾脏病的当前及未来药物治疗：肾脏保护中不断演变的靶点

Nat Rev Drug Discov. 2008 Nov;7(11):936-53. doi: 10.1038/nrd2685. Epub 2008 Oct 10.

Lancet. 2008 Aug 16;372(9638):547-53. doi: 10.1016/S0140-6736(08)61236-2.

Role of remission clinics in the longitudinal treatment of CKD.缓解诊所在慢性肾脏病纵向治疗中的作用。

J Am Soc Nephrol. 2008 Jun;19(6):1213-24. doi: 10.1681/ASN.2007090970. Epub 2008 Mar 19.

Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease.荟萃分析：肾素血管紧张素系统抑制剂单药治疗及联合治疗对肾病蛋白尿的影响

Ann Intern Med. 2008 Jan 1;148(1):30-48. doi: 10.7326/0003-4819-148-1-200801010-00190. Epub 2007 Nov 5.

Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.肾素-血管紧张素系统抑制剂及其他降压药物对肾脏结局的影响：系统评价与荟萃分析

Lancet. 2005 Dec 10;366(9502):2026-33. doi: 10.1016/S0140-6736(05)67814-2.

Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).血管紧张素转换酶抑制剂或钙通道阻滞剂与利尿剂治疗高危高血压患者的肾脏转归：抗高血压和降脂治疗预防心脏病发作试验（ALLHAT）报告

Arch Intern Med. 2005 Apr 25;165(8):936-46. doi: 10.1001/archinte.165.8.936.

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.延缓慢性肾病的进展：残余蛋白尿这一被忽视的问题。

Kidney Int. 2003 Jun;63(6):2254-61. doi: 10.1046/j.1523-1755.2003.00033.x.

Proteinuria and the risk of developing end-stage renal disease.蛋白尿与终末期肾病的发病风险

Kidney Int. 2003 Apr;63(4):1468-74. doi: 10.1046/j.1523-1755.2003.00868.x.

Longitudinal studies on the rate of decline in renal function with age.关于肾功能随年龄下降速率的纵向研究。

J Am Geriatr Soc. 1985 Apr;33(4):278-85. doi: 10.1111/j.1532-5415.1985.tb07117.x.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验